Therapeutic drug monitoring: The clinical practice;Suivi thérapeutique des médicaments (II): La pratique clinique

Revue Medicale Suisse

Volumn 4, Issue 165, 2008, Pages 1649-1660

  Widmer, Nicolas ^a   Grouzmann, Eric ^a   Fayet, Aurélie ^a   Csajka, Chantal ^a   Decosterd, Laurent A ^a   Buclin, Thierry ^a   Werner, Dominique ^a   Marchetti, Oscar ^a   Eap, Chin B ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPRENAVIR; BETA LACTAM; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; EFAVIRENZ; EVEROLIMUS; FLUCONAZOLE; GENTAMICIN; INDINAVIR; ITRACONAZOLE; LAMOTRIGINE; LITHIUM; LOPINAVIR; NELFINAVIR; NETILMICIN; NEVIRAPINE; PENICILLIN G; POSACONAZOLE; RAPAMYCIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; TOBRAMYCIN; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN; VORICONAZOLE;

CLINICAL PRACTICE; DRUG MONITORING; DRUG RESEARCH; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ANTIPARASITIC AGENTS; ANTITUBERCULAR AGENTS; CARDIOVASCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHOTROPIC DRUGS;

EID: 48349129448     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Widmer N, Csajka C, Werner D, et al. Suivi thérapeutique des médicaments (1) Les principes. Rev Med Suisse 2008;4:1644-8.
2. ** Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52(Suppl. 1):35S-43S.
3. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006;28:468-73.
4. Roberts JA, Lipman J. Antibacterial dosing in intensive care : Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45: 755-73.
5. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections : Prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45:2460-7.
6. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics : Experience with imipenem/cilastatin. Am J Med 1988;84:911-8.
7. Giannoni E, Moreillon P, Cotting J, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006;50:2563-8.
8. Jullien V, Lortholary O. Les relations pharmacocinétique- pharmacodynamique des antifongiques. Conséquences pour le suivi thérapeutique. Thérapie 2006; 61:209-17.
9. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11.
10. La Porte CJL, Back DJ, Blaschke T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy 2006; 3:3-14.
11. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-83.
12. * Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy : Recent developments. Ther Drug Monit 2006;28:720-5.
13. Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we ? Clin Chem Lab Med 2004;42:1204-11.
14. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring : A systematic review. Transplantation 2007;83:1525-35.
15. ** Baumann P, Hiemke C, Ulrich S, et al. Le dosage plasmatique des médicaments psychotropes à des fins thérapeutiques : recommandations du groupe d'experts AGNP-TDM. Rev Med Suisse 2006;2:1413-8.
16. e éd. Genève : Editions Médecine & Hygiène, 2002;71-4.
17. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005;27:539-43.
18. Eap CB. On the usefulness of therapeutic drug monitoring of methadone. Eur Addict Res 2000;6:31-3.
19. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants ? Clin Pharmacokinet 2000;38:191-204.
20. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs : When is monitoring needed ? Clin Pharmacokinet 2006;45:1061-75.
21. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004;42:1228-55.
22. Jurgens G, Graudal NA, Kampmann JP. Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet 2003;42:647-63.
23. de Jonge ME, Huitema AD, Schellens JH, et al. Individualised cancer chemotherapy : Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation : A review. Clin Pharmacokinet 2005;44:147-73.
24. Petros WM, Evans E. Anticancer agents. In : ME Burton, LM Shaw, JJ Schentag, et al. Applied pharmacokinetics and pharmacodynamics : Principles of therapeutic drug monitoring. 4th ed. Baltimore : Lippincott Williams & Wilkins, 2006:617-36.
25. Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib free plasma levels and target genotype with efficacy and tolerability (in press). Br J Cancer 2008;98:1633-40.
26. Pesce AJ, Rashkin M, Kotagal U. Standards of laboratory practice : Theophylline and caffeine monitoring. National Academy of clinical biochemistry. Clin Chem 1998;44:1124-8.
27. Wusk B, Kullak-Ublick GA, Rammert C, et al. Thiopurine S-methyltransferase polymorphisms : Efficient screening method for patients considering taking thiopurine drugs. Eur J Clin Pharmacol 2004;60:5-10.
28. Wusk B, Kullak-Ublick GA, Rammert C, et al. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004;16: 1407-13.
29. Widmer N, Buclin T, Augsburger M. Dépistage des substances d'abus. Pharma-Flash 2008;35:2-3.
30. e éd. Bâle : Documed, 2005;19-29.
31. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003;26:876-9.
32. ** Marquet P. Suivi thérapeutique pharmacologique : pour l'adaptation de posologie de médicaments. Paris : Elsevier, 2004.
33. Tox-Zentrum. Mesures d'urgences dans les intoxications aiguës. www.toxi.ch/
34. Warner A, Privitera M, Bates D. Standards of laboratory practice : Antiepileptic drug monitoring. Clin Chem 1998;44:1085-95.
35. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure : A propensity-matched study of the DIG trial. Int J Cardiol 2008;123:138-46.
36. * Rentsch K, Fathi M, Grignaschi N, et al. Monographies on drugs, which are frequently analysed in the course of Therapeutic Drug Monitoring. J Lab Med 2005;29:287-97.
37. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694-703.
38. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9.
39. Demetri GD, Wang Y, Wehrle E, et al. Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST) (abstract, oral presentation). In Gastrointestinal Cancers Symposium 2008.
40. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates : An unnecessary exercise ? Pediatrics 2007; 119:936-40.